| Wukui Huang,Dengyao Liu,Lina You,Shufa Yang,Mo Liu,Peng Gu,Pingju Wang,Baikere Pahaerding,Xiwen Fan. Jinlong capsule decreases adverse reactions after transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma. Oncol Transl Med, 2015, 1: 87-91. |
| Jinlong capsule decreases adverse reactions after transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma |
| Received:October 20, 2014 Revised:March 31, 2015 |
| View Full Text View/Add Comment Download reader |
| KeyWord:Jinlong capsule; primary hepatocellular carcinoma (PHC); transcatheter arterial chemoembolization (TACE); adverse reaction |
| Author Name | Affiliation | E-mail | | Wukui Huang | Department of Intervention Radiology, The Affilited Tumor Hospital of XinJiang Medical University, Urmqi, 830011, China | huangwukui1982@sina.com | | Dengyao Liu | Department of Intervention Radiology, The Affilited Tumor Hospital of XinJiang Medical University, Urmqi, 830011, China | liudy1127@qq.com | | Lina You | Department of Traditional Chinese Medical, The Fifth Affilited Hospital of XinJiang Medical University, Urmqi, 830011, China. | | | Shufa Yang | Department of Intervention Radiology, The Affilited Tumor Hospital of XinJiang Medical University, Urmqi, 830011, China | | | Mo Liu | Department of Intervention Radiology, The Affilited Tumor Hospital of XinJiang Medical University, Urmqi, 830011, China | | | Peng Gu | Department of Intervention Radiology, The Affilited Tumor Hospital of XinJiang Medical University, Urmqi, 830011, China | | | Pingju Wang | Department of Intervention Radiology, The Affilited Tumor Hospital of XinJiang Medical University, Urmqi, 830011, China | | | Baikere Pahaerding | Department of Intervention Radiology, The Affilited Tumor Hospital of XinJiang Medical University, Urmqi, 830011, China | | | Xiwen Fan | Department of Intervention Radiology, The Affilited Tumor Hospital of XinJiang Medical University, Urmqi, 830011, China | 1005978212@qq.com |
|
| Hits: 6647 |
| Download times: 7283 |
| Abstract: |
| Objective: The aim of this study was to analyze whether Jinlong capsule could decrease adverse reactions after transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma.
Methods: Eighty-two patients with hepatocellular carcinoma were randomly divided into the control group and experimental group. On the first day after TACE, the experimental group started receiving four Jinlong capsules orally three times daily, whereas the control group did not receive the treatment.
Results: The incidences of erythropenia and thrombocytopenia in the experimental group was lower than those in the control group (P = 0.040 and 0.033, respectively). The differences in serum levels of aminotransferase, albumin, otassium, and sodium between the two groups were significant (P = 0.034, 0.034, 0.013, and 0.044, respectively). The mean durations of stomachache and abdominal distension in the experimental group was significantly shorter than those in the control group (P = 0.004 and 0.021, respectively). However, there were no significant differences in the incidences of nausea, fever, and vomiting between the two groups (P = 0.490, 0.495, and 0.585, respectively).
Conclusion: The reduction in the incidence rate and duration of partial adverse reactions after TACE was observed in hepatocellular carcinoma patients treated with Jinlong capsule compared to untreated patients, suggesting possible beneficial effects exerted by Jinlong capsule on the reduction of TACE-induced liver damage, thereby improving liver function and, consequently, the quality of life. |
| Close |
|
|
|